Eng Hooi (Cheryl) Tan
BSc (Pharm), MPH, PhD
Postdoctoral Research Assistant in Pharmaco-epidemiological Methods
As a pharmacoepidemiologist, I apply methods to investigate the drug utilisation and comparative effectiveness and safety of medications using routinely collected healthcare data. I am currently involved in a study to assess the comparability of osteoporosis treatment groups via negative control outcomes analysis. I hope to support reliable evidence generation that translates into better patient care.
I completed my PhD at the National University of Singapore (NUS). My thesis explored the detection of drug-induced liver injury in electronic medical records. I obtained my Master of Public Health (MPH) from the University of Sydney and graduated from NUS with a BSc (Pharmacy) as an ASEAN scholar.
My working experience includes practicing as a pharmacist in a tertiary hospital and an oncology centre. While working on my PhD, I was also a research associate managing a randomised controlled trial evaluating the use of SMS reminders to improve medication adherence in women with breast cancer.
I joined NDORMS in June 2020.
Recent publications
-
The impact of the COVID-19 pandemic on short-term cancer survival in the United Kingdom: a cohort analysis
Preprint
Barclay NL. et al, (2023)
-
Risk of adverse events following the initiation of antihypertensives in older people with complex health needs: a self-controlled case series in the United Kingdom.
Journal article
Jödicke AM. et al, (2023), Age ageing, 52
-
Drug utilization analysis of osteoporosis medications in seven European electronic health databases.
Journal article
Tan EH. et al, (2023), Osteoporos int
-
Safety Outcomes of Selective Serotonin Reuptake Inhibitors in Adolescent Attention-Deficit/Hyperactivity Disorder with Comorbid Depression: The ASSURE Study - CORRIGENDUM.
Journal article
Kim C. et al, (2023), Psychol med
-
Evaluating the Comparative Effectiveness and Safety of Repurposed Drugs for COVID-19
Conference paper
Tan EH. et al, (2022)